ArticleClinical rheumatology2026
Elevated levels of nitrotyrosine-modified protein adducts and their association with the severity of primary sjogren's syndrome and secondary sjogren's syndrome with rheumatoid arthritis in Taiwanese Patients.
Article in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Untargeted metabolomics reveals differential metabolic pathways and biomarkers in the acute phase of Kawasaki disease.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
objectivesPrimary Sjogren's syndrome (pSS) is an autoimmune condition characterized by glandular dysfunction. The roles of nitrotyrosine-modified (NT)-protein adducts and anti-NT-peptide adduct autoantibodies in disease progression and their potential as biomarkers remain underexplored. In this study, we assessed NT-protein adducts, related autoantibodies, and their associations with disease progression in pSS patients and their transformation into secondary SS with rheumatoid arthritis (RA-sSS).
methodsThe serum levels of proteins, NT-protein adducts, and autoantibodies against novel pSS-specific component C3 (C3)
resultsNT-protein adduct levels progressively increased across groups, reflecting increasing nitrosative stress. Elevated NT-protein adducts (OR = 4.542) and reduced levels of specific autoantibodies, such as IgA anti-C3
conclusionsOur findings suggest that elevated NT-protein adducts may signify an increased risk for disease progression in pSS patients and transformation to RA-sSS. Machine learning integration of NT-protein adducts, autoantibodies, and traditional biomarkers may enhance early SS diagnosis. Key Points • The elevated nitrotyrosine-modified protein adducts may emerge as significant biomarkers of disease progression in pSS and its transformation into RA-sSS.. • The reduced specific autoantibodies, such as IgA anti-C3
Indexed as
Identifiers
41174274What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.